Vincerx Pharma, Inc.
VINC
$0.8145
$0.00550.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.75% | -5.22% | -35.02% | -54.29% | -22.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.90% | -38.92% | -51.47% | -57.57% | -38.37% |
| Operating Income | 18.90% | 38.92% | 51.47% | 57.57% | 38.37% |
| Income Before Tax | 12.92% | 84.35% | 15.16% | 56.04% | 46.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.92% | 84.35% | 15.16% | 56.04% | 46.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.92% | 84.35% | 15.16% | 56.04% | 46.64% |
| EBIT | 18.90% | 38.92% | 51.47% | 57.57% | 38.37% |
| EBITDA | 18.92% | 38.96% | 51.51% | 57.62% | 38.41% |
| EPS Basic | 40.81% | 88.86% | 16.00% | 56.52% | 47.29% |
| Normalized Basic EPS | 40.80% | 88.86% | 15.99% | 56.50% | 42.86% |
| EPS Diluted | 40.81% | 88.86% | 16.00% | 56.52% | 47.29% |
| Normalized Diluted EPS | 40.80% | 88.86% | 15.99% | 56.50% | 42.86% |
| Average Basic Shares Outstanding | 47.09% | 40.40% | 1.00% | 1.10% | 1.24% |
| Average Diluted Shares Outstanding | 47.09% | 40.40% | 1.00% | 1.10% | 1.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
